Company intelligence / Profile preview

AEIR Therapeutics

State College, Pennsylvania, United States

Ownership: Private
Development stage: Other

Overview

AEIR Therapeutics is a clinical-stage biotechnology company focused on developing novel small molecule inhibitors targeting the Aryl Hydrocarbon Receptor (AHR) for the treatment of cancer. The company's lead program, AEIR-101, is designed to modulate the immune system's response to tumors by blocking the immunosuppressive effects of AHR activation in the tumor microenvironment. By inhibiting AHR, AEIR Therapeutics aims to enhance the efficacy of existing immunotherapies and provide new treatment options for patients with refractory solid tumors. The company's research is based on foundational work regarding the role of AHR in immune regulation and oncogenesis conducted at Pennsylvania State University.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on AEIR Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AEIR Therapeutics.

Explore the full profile